Narrow-band imaging versus Lugol chromoendoscopy for esophageal squamous cell cancer screening in normal endoscopic practice: randomized controlled trial.


Journal

Endoscopy
ISSN: 1438-8812
Titre abrégé: Endoscopy
Pays: Germany
ID NLM: 0215166

Informations de publication

Date de publication:
07 2021
Historique:
aheadofprint: 22 07 2020
pubmed: 23 7 2020
medline: 21 7 2021
entrez: 23 7 2020
Statut: ppublish

Résumé

Narrow-band imaging (NBI) is as sensitive as Lugol chromoendoscopy to detect esophageal squamous cell carcinoma (SCC) but its specificity, which appears higher than that of Lugol chromoendoscopy in expert centers, remains to be established in general practice. This study aimed to prove the superiority of NBI specificity over Lugol chromoendoscopy in the detection of esophageal SCC and high grade dysplasia (HGD) in current general practice (including tertiary care centers, local hospitals, and private clinics). This prospective randomized multicenter trial included consecutive patients with previous or current SCC of the upper aerodigestive tract who were scheduled for gastroscopy. Patients were randomly allocated to either the Lugol or NBI group. In the Lugol group, examination with white light and Lugol chromoendoscopy were successively performed. In the NBI group, NBI examination was performed after white-light endoscopy. We compared the diagnostic characteristics of NBI and Lugol chromoendoscopy in a per-patient analysis. 334 patients with history of SCC were included and analyzed (intention-to-treat) from 15 French institutions between March 2011 and December 2015. In per-patient analysis, sensitivity, specificity, positive and negative likelihood values were 100 %, 66.0 %, 21.2 %, and 100 %, respectively, for Lugol chromoendoscopy vs. 100 %, 79.9 %, 37.5 %, and 100 %, respectively, for NBI. Specificity was greater with NBI than with Lugol ( As previously demonstrated in expert centers, NBI was more specific than Lugol in current gastroenterology practice for the detection of early SCC, but combined approaches with both NBI and Lugol could improve the detection of squamous neoplasia.

Sections du résumé

BACKGROUND
Narrow-band imaging (NBI) is as sensitive as Lugol chromoendoscopy to detect esophageal squamous cell carcinoma (SCC) but its specificity, which appears higher than that of Lugol chromoendoscopy in expert centers, remains to be established in general practice. This study aimed to prove the superiority of NBI specificity over Lugol chromoendoscopy in the detection of esophageal SCC and high grade dysplasia (HGD) in current general practice (including tertiary care centers, local hospitals, and private clinics).
METHODS
This prospective randomized multicenter trial included consecutive patients with previous or current SCC of the upper aerodigestive tract who were scheduled for gastroscopy. Patients were randomly allocated to either the Lugol or NBI group. In the Lugol group, examination with white light and Lugol chromoendoscopy were successively performed. In the NBI group, NBI examination was performed after white-light endoscopy. We compared the diagnostic characteristics of NBI and Lugol chromoendoscopy in a per-patient analysis.
RESULTS
334 patients with history of SCC were included and analyzed (intention-to-treat) from 15 French institutions between March 2011 and December 2015. In per-patient analysis, sensitivity, specificity, positive and negative likelihood values were 100 %, 66.0 %, 21.2 %, and 100 %, respectively, for Lugol chromoendoscopy vs. 100 %, 79.9 %, 37.5 %, and 100 %, respectively, for NBI. Specificity was greater with NBI than with Lugol (
CONCLUSIONS
As previously demonstrated in expert centers, NBI was more specific than Lugol in current gastroenterology practice for the detection of early SCC, but combined approaches with both NBI and Lugol could improve the detection of squamous neoplasia.

Identifiants

pubmed: 32698233
doi: 10.1055/a-1224-6822
doi:

Substances chimiques

Coloring Agents 0
Iodides 0

Banques de données

ClinicalTrials.gov
['NCT04224896']

Types de publication

Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

674-682

Commentaires et corrections

Type : CommentIn

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Auteurs

Mélissa Gruner (M)

Gastroenterology Division, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

Angélique Denis (A)

Pole de Santé Publique, Statistics and Medical Research Department, Hospices Civils de Lyon, Lyon, France.

Claude Masliah (C)

Gastroenterology Division, Clinique Mutualiste de l'Estuaire, Saint Nazaire, France.

Morgane Amil (M)

Gastroenterology Division, Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, France.

Elodie Metivier-Cesbron (E)

Gastroenterology Division, Centre Hospitalo-Universitaire Larrey, Angers, France.

Dominique Luet (D)

Gastroenterology Division, Centre Hospitalo-Universitaire Larrey, Angers, France.

Medhi Kaasis (M)

Gastroenterology Division, Centre Hospitalier de Cholet, Cholet, France.

Emmanuel Coron (E)

Hepatogastroenterology Department, Hotel Dieu, Nantes, France.

Marc Le Rhun (M)

Hepatogastroenterology Department, Hotel Dieu, Nantes, France.

Stéphane Lecleire (S)

Gastroenterology Division, Hôpital Charles Nicolle, Centre Hospitalo-Universitaire, Rouen, France.

Michel Antonietti (M)

Gastroenterology Division, Hôpital Charles Nicolle, Centre Hospitalo-Universitaire, Rouen, France.

Jean-Louis Legoux (JL)

Gastroenterology Division, Hôpital La Source, Centre Hospitalier Régional, Orléans, France.

Laurent Lefrou (L)

Gastroenterology Division, Hôpital La Source, Centre Hospitalier Régional, Orléans, France.

Pascal Renkes (P)

Gastroenterology Division, Hôpital Clinique Claude Bernard, Metz, France.

Anne-Laure Tarreirias (AL)

Gastroenterology Division, Hôpital Foch, Suresnes, France.

Philippe Balian (P)

Gastroenterology Division, Hôpital Foch, Suresnes, France.

Philippe Rey (P)

Gastroenterology Division, Hôpital d'Instruction des Armées, Legouest, Metz, France.

Bénédicte Prost (B)

Gastroenterology Division, Centre Hospitalier Saint Joseph Saint Luc, Lyon, France.

Christophe Cellier (C)

Gastroenterology Division, Hôpital Européen Georges Pompidou, Paris, France.

Gabriel Rahmi (G)

Gastroenterology Division, Hôpital Européen Georges Pompidou, Paris, France.

Elia Samaha (E)

Gastroenterology Division, Hôpital Européen Georges Pompidou, Paris, France.

Serge Fratte (S)

Gastroenterology Division, Centre Hospitalier Régional, Belfort, France.

Béatrice Guerrier (B)

Gastroenterology Division, Centre Hospitalier Bourg en Bresse, Bourg en Bresse, France.

Verena Landel (V)

Direction Recherche Clinique et Innovations, Hospices Civils de Lyon, Lyon, France.

Sandrine Touzet (S)

Pole de Santé Publique, Statistics and Medical Research Department, Hospices Civils de Lyon, Lyon, France.

Thierry Ponchon (T)

Gastroenterology Division, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
Lyon 1 University Claude Bernard, Lyon, France.
INSERM U1032, LabTAU, Lyon, France.

Mathieu Pioche (M)

Gastroenterology Division, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
Lyon 1 University Claude Bernard, Lyon, France.
INSERM U1032, LabTAU, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH